

Date: 27th May 2022

To, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Sub: Audited Annual Financial Results for year ended 31st March 2023

In pursuant to Regulations 30 & 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, this is to intimate that the Board of Directors of the Company, at its Meeting held on Saturday, 27th May 2023 at 12.30 pm has inter alia considered and approved Audited Annual Financial Results of Company for the year ended on 31st March 2023 along with Report thereon.

The Board Meeting was concluded on 01.55 pm

We would request you to take the above intimation on records.

For, Vaidya Sane Ayurved Laboratories Limited

Abhishek Deshpande

* balim Company Secretary & Compliance Officer



1/3, Shree Vivekanand CHS Ltd., Guru Mandir Road, Saraswat Colony, Dombivli (East) 421 201.

M: 9223 543 842 / LL: 0251 - 2473000

Email: amit@aamco.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTERIES LIMITED

To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

- We have reviewed the accompanying Statement of Standalone Audited Financial Results of VAIDYA SANE
 AYURVED LABROTERIES LIMITED (the "Company"), for the year ended March 31, 2023 (the "Statement"),
 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing
 Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Standalone Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at March 31, 2023, and of its results of operations and its Standalone cash flows for the year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed.

For A A Mohare & Co.

Chartered Accountants (FRN: 114152W)

FRN 114152W

CA Amit A Mohare

Partner

Membership No.: 148601

Place: Thane Date: 27/05/2023

UDIN : 23148601BGWJJP6375

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO.: L73100PN1999PLC013509

Satndalone Statement of profit and loss for the Half year ended 31st March 2023 and year ended March 31,2023

Particulars	For the Half year ended March 31,2023	For the Half Year Ended March 31, 2022	For the Year Ended March 31,2023	For the year ended March 31, 2022
Revenue				
Revenue from operations	5,349.81	4,314.64	9,902.54	7,471.05
Other income	53.58	33.78	136.09	33.88
Total revenue	5,403.40	4,348.42	10,038.63	7,504.93
Expenses				7,504.55
Cost of materials consumed	1,455.82	1,233.30	2,762.28	2,206.58
Employee benefit expenses	1,109.37	923.71	2,181.00	1,818.67
Finance costs	7.45	9.30	18.75	20.18
Depreciation and amortisation expense	144.26	111.12	259.79	228.57
Other expenses	2,395.78	1,728.82	4,125.77	2,756.04
Total expenses	5,112.69	4,006.25	9,347.59	7,030.04
Profit / (loss) before prior period adjustments & tax.	290.71	342.17	691.04	474.89
Prior period adjustments			031.04	4/4.05
Profit / (loss) before extraordinary items and	290.71	342.17	691.04	474.89
tax		342.27	031.04	4/4.09
Extraordinary items				
Profit / (loss) before tax	290.71	342.17	691.04	474.89
Tax expense	-	312.27	032.04	474.65
Current tax	72.96	101.89	172.26	119.14
Deferred tax (expense)/income	(0.14)	28.86	(0.22)	8.85
Profit for the year	217.89	211.43	519.00	346.90
Earnings per equity share		222113	313.00	340.50
[Nominal value per share Rs. 10 (F.Y. 2021-22 - Rs.10)]			1	
Basic	2.07	2.01	4.94	8.00
Diluted	2.07	2.01	4.94	8.00

Notes:

- 1) The Audited Financial statement were reviewed by the audit committee and taken on rcord by the Board of directors at their meeting held on 27th May, 2023
- 2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Audit Reports on the aforesaid audited financial results for the half year & year ended 31st March. 2023, which were also approved by the Audit Committee and board at their meeting held on Saturday,27th May, 2023.
- 3) The Earning Per Sare (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- 4) As per MCA Notification Wited 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adapted INO-AS for preparation of financial results.
- 5) The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below,

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600.00	1,452.78	147.22
General Corporate Purpose	372.98	372.98	0.00
Total	1,972.98	1,825.76	147.22

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

For and on behalf of the Board of Directors of

Membership No. 148601 Place: Thane

Date: 27/05/2023 UDIN: 23 14 866 BGWJJP637 Vaidya Sane Ayurved Laboratories Ltd

Vidyut Ghag MD & CEO Whole Time Director

DIN: 00679851

Date: 27/05/2023

Place : Thane

DIN: 09299252

Date: 27/05/2023 Place : Thane

Date: 27/05/2023 Place : Thane

bhishek Deshpande

Company Secretary

Date: 27/05/2023 Place : Thane

Darshan Shah



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO.: L73100PN1999PLC013509

Standalone Balance Sheet as at March 31, 2023

	Particulars		As at	Amounts in Lakh As at
_	raticulars		th 31, 2023	March 31, 202
	EQUITY AND LIABILITIES			
1	1. Shareholders' Funds	ă		*
1	Share Capital		1,051.35	1,051.3
1	Reserves and Surplus		3,029.63	2,536.
١			4,080.98	3,588.
	2. Non-Current Liabilities		` .	
	Long-Term Borrowings			
١	Deferred Tax Liabilities (Net)		-	-
1	Long-Term Provisions	1	4.52	4.
ı	Tong remitrovisions		155.32	156.
1	3. Current Liabilities		159.84	161.
l.	Short-Term Borrowings			
١	Trade Payables	1	13.40	106.
	(a) Total outstanding dues of micro enterprises and small e		-22000	
1	(b) Total outstanding dues of creditors other than micro er	hterprises	159.65	145.0
ı	Other Current Liabilities	terprises and small enterp	736.29	592.
ı	Short-Term Provisions		329.59	297.
ı	SHORETERM FLOVISIONS		48.13	109.
١			1,287.06	1,251.0
	TOTAL		5,527.88	5,000.5
4	ASSETS			
1	1. Non-Current Assets			
ı	Property, Plant & Equipment			
ı	Tangible assets	1	1,843.43	1,596.4
ı	Intangible assets		251.34	104.
ı	Capital work in progress		167.21	123.0
ı	Non-Current Investments		105.36	488.3
ı	Long-Term Loans and Advances		278.24	140.8
ı	The state of the s		2,645.58	2,452.7
,	2. Current Assets			
ľ	Current Investment		1 270 54	
	Inventory		1,379.51	1,660.7
	Trade receivables	1	341.38	150.0
l	Cash and Bank Balances		646.40	355.8
	Short-Term loans and advances		175.15	256.0
	Short-refin loans and advances		339.86	125.0
			2,882.30	2,547.8
	TOTAL		5,527.88	E 000 F
1	TW THE		3,327.00	5,000.5

As per our report of even date

Chartered Accountants (FRN 114152W)

For A A Mohare and Co.

For and on behalf of the Board of Directors of Vaidya Sane Ayurved Laboratories Ltd

Partner

Membership No. 148601

Rohit Sane MD & CEO DIN: 00679851 Vidyut Ghag Whole Time Director DIN: 09299252

Abhishek Deshpande Company Secretary

Darshan Shah CFO

Place: Thane

Date: 27/05/2023

Place: Thane

Place: Thane Date: 27/05/2023 Date: 27/05/2023

Place: Thane Date: 27/05/2023 Place: Thane Date: 27/05/2023



CIN NO.: L73100PN1999PLC013509

Standalone Cash flow statements for the year ended March 31, 2023

March 31, 2023 Marc	Particulars	For th	Amounts in Lakh
Adjustments for:			
Adjustments for: Depreciation and Amortization of Property, Plant and Equipment Interest income Note of the interest income Dividend income (0.05) (A. CASH FLOW FROM OPERATING ACTIVITIES :		111011111111111111111111111111111111111
Adjustments for: Depreciation and Amortization of Property, Plant and Equipment Depreciation and Amortization of Property, Plant and Equipment Depreciation and Amortization of Property, Plant and Equipment Dividend income (0.05) (0.1 Excess balance written off Excess balance written off (2.04) - Finance costs (2.04) - Finance costs (2.04) - Sa3.67 (689.1 Adjustments for Changes in Working Capital changes Adjustments for Changes in Working Capital (Increase)/decrease in Inventory (Increase)/decrease in Inventory (Increase)/decrease in Inventory (Increase)/decrease in Interde Receivables (Increase)/decrease in Interde Receivables (Increase)/decrease in Interde Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Interde Payables Increase/(decrease) in Interde Payables Increase/(decrease) in Interde Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Interde Payables Increase/(decrease) in Interde Term Provisions Increase/(decrease) in Interde Term Provisions Increase/(decrease) in Interder Current Liabilities Increase/(decrease) in Interder Current Liabilities Increase/(decrease) in Interder Liabilities Interder Received Interd	Net Profit before tax	601.04	474.00
Interest income (87.27) (144.	Adjustments for:	091.04	4/4.85
Interest income (87.27) (144.	Depreciation and Amortization of Property, Plant and Equipment	250 70	220 5
Divided income (0.05) (0.0			A Contract of the Contract of
Rent Income	Dividend income		Carl Harm
Excess balance written off Finance costs Operating cash flows before Working Capital changes Adjustments for Changes in Working Capital (Increase)/decrease in Inventory (191.32) 11.4 (Increase)/decrease in Inventory (191.32) 11.4 (Increase)/decrease in Inventory (191.32) 11.4 (Increase)/decrease in Trade Receivables (291.88) (92.0 (191.32) Increase/(decrease) in Short term Loans and Advances (335.02) (1795.3 (Rent income		
18.75 20.15	Excess balance written off		,
Adjustments for Changes in Working Capital (Increase)/decrease in Inventory (191.32) (11.4 (291.88) (92.0 (291.88) (192.0 (201.88) (192.0 (201.88) (Finance costs		Mark Const
(Increase)/decrease in Inventory (Increase)/decrease in Trade Receivables (Increase)/decrease in Trade Receivables (Increase)/decrease in Short term Loans and Advances (Increase)/decrease in Short term Loans and Advances (Increase)/decrease) in Trade Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Cash Georgia (1212) Increase/(decrease) in Cash Georgia	Operating cash flows before Working Capital changes		689.76
(Increase)/decrease in Inventory (Increase)/decrease in Trade Receivables (Increase)/decrease in Trade Receivables (Increase)/decrease in Short term Loans and Advances (Increase)/decrease in Short term Loans and Advances (Increase)/decrease) in Trade Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Trade Payables Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Cash Georgia (1212) Increase/(decrease) in Cash Georgia	Adjustments for Changes in Working Capital		
(Increase)/decrease in Trade Receivables (291.88) (92.0 (Increase)/decrease in Short term Loans and Advances (335.02) (1,795.3 Increase/(decrease) in Trade Payables 161.45 63.0 Increase/(decrease) in Other Current Liabilities 32.27 (90.5 Increase/(decrease) in Long - Term and Short - Term Provisions 10.16 1.7 CASH GENERATED FROM OPERATIONS 219.33 (1,212.3 Taxes Paid (262.26) (119.1 NET CASH FROM OPERATING ACTIVITIES (42.93) (1,331.4 CASH FLOW FROM INVESTING ACTIVITIES (42.93) (1,331.4 Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets (697.91) (317.2 Proceeds from Fixed deposit (697.91) (317.2 Rent Income (105.36) - Dividend received 0.05 0.0 Interest Received 0.05 0.0 NET CASH USED IN INVESTING ACTIVITIES 99.95 (752.0 CASH FLOW FROM FINANCING ACTIVITIES 99.95 (752.0 CASH FLOW FROM FINANCING ACTIVITIES - 277.1 Proceeds from the right issue of shares <		(101.22)	
(Increase)/decrease in Short term Loans and Advances Increase/(decrease) in Trade Payables Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Long - Term and Short - Term Provisions CASH GENERATED FROM OPERATIONS Taxes Paid NET CASH FROM OPERATING ACTIVITIES CASH FLOW FROM INVESTING ACTIVITIES Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received Interest Received NET CASH USED IN INVESTING ACTIVITIES Proceeds from the issue of shares Proceeds from the issue of shares Proceeds from the insue of shares Proceeds f		(10000000000000000000000000000000000000	Later Control of the
Increase/(decrease) in Trade Payables Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Long - Term and Short - Term Provisions CASH GENERATED FROM OPERATIONS Taxes Paid NET CASH FROM OPERATIONS (42.93) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Long - Term and Short - Term Provisions Investment in Queta (262.26) Increase/(decrease) in Long - Term and Short - Term Provisions Investment in quoted (42.93) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Borrowings Increase/(decrease) in Borrowings Increase/(decrease) in Congress (19.33) Increase/(decrease) in Congress (19.33) Increase/(decrease) in Borrowings Increase/(Decrease) in Borrowings Interim Dividend paid Interim Dividend		1.77.75ET 16.75ET 16.7	
Increase/(decrease) in Other Current Liabilities Increase/(decrease) in Long - Term and Short - Term Provisions Increase/(decrease) in Long - Term and Short - Term Provisions CASH GENERATED FROM OPERATIONS Taxes Paid NET CASH FROM OPERATING ACTIVITIES CASH FROM OPERATING ACTIVITIES Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received NET CASH USED IN INVESTING ACTIVITIES Proceeds from the issue of shares Proceeds from the right issue of shares Proceeds from the right issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs INTERICATION OF INTERIOR ACTIVITIES FINANCE COST INTERIOR OF			
Increase/(decrease) in Long - Term and Short - Term Provisions 10.16 1.7		1	63.08
CASH GENERATED FROM OPERATIONS 219.33 (1,212.3) (1,212.3) (1,212.3) (1,212.3) (1,212.3) (1,212.3) (1,212.3) (1,213.3) (1,212.3) (1,213.3) (1,212.3) (1,213.3) (1,212.3) (1,231.4)			*********
Taxes Paid NET CASH FROM OPERATING ACTIVITIES CASH FLOW FROM INVESTING ACTIVITIES Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets Proceeds from sale of tangible/intangible assets Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received NET CASH USED IN INVESTING ACTIVITIES Proceeds from the right issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs (42.93) (1.9.13.4.6. (697.91) (317.2 (105.36) -			1.74
NET CASH FROM OPERATING ACTIVITIES CASH FLOW FROM INVESTING ACTIVITIES Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets Proceeds from sale of tangible/intangible assets Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received NET CASH USED IN INVESTING ACTIVITIES Proceeds from the issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (42.93) (1,331.4 (697.91) (10.317.2 (10.317	Taxes Paid		1 TANK 1 TO SECOND
CASH FLOW FROM INVESTING ACTIVITIES Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received NET CASH LUSED IN INVESTING ACTIVITIES CASH FLOW FROM FINANCING ACTIVITIES Proceeds from the issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs (697.91) (317.2 (18.75.2 (19.79.1) (19.79.35) (487.1 (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (487.1 (19.79.35) (19.79.35) (19.79.35) (19.79.36) (1	NET CASH FROM OPERATING ACTIVITIES		
18.3 19.3	S. CASH FLOW FROM INVESTING ACTIVITIES		1,5,5
18.3 19.3	Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets	(607 01)	(217.20
Investment in quoted / unquoted shares Proceeds from Fixed deposit Rent Income Dividend received Interest Received Interest Received NET CASH USED IN INVESTING ACTIVITIES CASH FLOW FROM FINANCING ACTIVITIES Proceeds from the issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs (105.36) (487.1 (99.35) (487.1 (487.1 (90.50) (90.50) (90.50) (90.50) (90.50) (90.60	Proceeds from sale of tangible/intangible assets	(037.31)	110000000000000000000000000000000000000
Proceeds from Fixed deposit Rent Income Dividend received Dividend received Interest Received NET CASH USED IN INVESTING ACTIVITIES Proceeds from the issue of shares Proceeds from the right issue of shares Share premium Increase / (Decrease) in Borrowings Interim Dividend paid Finance costs FINANCING ACTIVITIES (92.93) FINANCING ACTIVITIES (18.75) FINANCING ACTIVITIES (20.1		/105 261	18.30
Rent Income 46.55 19.1		191000000000000000000000000000000000000	/407.13
Dividend received 10.05 10.00	Rent Income		1127 200
Interest Received	Dividend received	(HORSE CO.)	- 7 (7) (7)
NET CASH USED IN INVESTING ACTIVITIES 99.95 (752.0 CASH FLOW FROM FINANCING ACTIVITIES - 277.1 Proceeds from the issue of shares - 76.7 Proceeds from the right issue of shares - 1,910.8 Share premium - 1,910.8 Increase / (Decrease) in Borrowings (92.93) 4.6 Interim Dividend paid (26.28) - Finance costs (18.75) (20.1	Interest Received		1000000
Proceeds from the issue of shares - 277.1 Proceeds from the right issue of shares - 76.7 Share premium - 1,910.8 Increase / (Decrease) in Borrowings (92.93) 4.6 Interim Dividend paid (26.28) - Finance costs (18.75) (20.1	NET CASH USED IN INVESTING ACTIVITIES		(752.09
Proceeds from the right issue of shares 76.77 Share premium 1,910.8 Increase / (Decrease) in Borrowings (92.93) 4.6 Interim Dividend paid (26.28) - Finance costs (18.75) (20.1	. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from the right issue of shares - 76.7 Share premium - 1,910.8 Increase / (Decrease) in Borrowings (92.93) 4.6 Interim Dividend paid (26.28) - Finance costs (18.75) (20.1	Proceeds from the issue of shares		277 12
Share premium - 1,910.8	Proceeds from the right issue of shares		
Increase / (Decrease) in Borrowings			The second secon
Interim Dividend paid (26.28) Finance costs (18.75) (20.1			
Finance costs (18.75) (20.1		10.5050.0550.05	4.69
NET CACH LICED IN FINANCIAL ACTIVITIES			/20.10
	NET CASH USED IN FINANCIAL ACTIVITIES		2,249.18

CASH AND CASH EQUIVALENTS:

Net increase in Cash and Cash Equivalents

Cash and Cash Equivalents at beginning of the period

Cash and Cash Equivalents as end of the period

Particulars	As at March 31, 2023	As at March 31, 2022
On current accounts	157.21	77.30
Deposits with original maturity of less than 3 months	-	150.39
Cash on hand	17.94	28.40
	175.15	256.09

As per our report of even date

For A A Mohare and Co. Chartered Accountants (FRN 114152W) For and on behalf of the Board of Directors of

Vaidya Sane Ayurved Laboratories Ltd

Amit Mohare Partner Membership No. 148601

Place: Thane

Date: 27/05/2023 23 14860 | BGWJJ

Rohit Sane MD & CEO DIN: 00679851

Place: Thane Date: 27/05/2023 Vidyut Ghag Whole Time Director

DIN: 09299252 Place : Thane Date: 27/05/2023

Abhishek Deshpande Darshan Shah Company Secretary

Place : Thane Date: 27/05/2023 CFO

(80.94)

256.09

165.61

90.48

256.09

Place : Thane Date: 27/05/2023





1/3, Shree Vivekanand CHS Ltd., Guru Mandir Road, Saraswat Colony, Dombivli (East) 421 201.

M: 9223 543 842 / LL: 0251 - 2473000

Email: amit@aamco.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTERIES LIMITED

To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

- 1. We have reviewed the accompanying Statement of Consolidated Audited Financial Results of VAIDYA SANE AYURVED LABROTERIES LIMITED (the "Company" or "Parent") and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), and its share of the net profit after tax for the year ended March 31, 2023 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement of Consolidated financial information based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
- 4. The Statement includes the results of the following entity:

Sr. No.	Name of the Subsidiary	No. of Shares	Face Value	Value per Share paid	% holding in Company	Investment Value
1	Joint Healing Services Pvt Ltd	9900	10	10	99.00	99,000
2	F-health Accelerators Pvt Ltd	8000	10	10	80.00	80,000



- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at March 31, 2023, and of its results of operations and its cash flows for the year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed.
- 6. There are no uncertainties arising from the COVID 19 pandemic on which our conclusion on the Statement is modified in respect of this matter unless specifically mentioned.

For A A Mohare & Co.

Chartered Accountants (FRN: 114152W)

FRN 114152W

CA Amit A Mohare

Partner

Membership No.: 148601

Place: Thane
Date: 27/05/2023

UDIN : 23148601BGWJJO4191

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO. : L73100PN1999PLC013509

Consolidated Statement of profit and loss for the Half year ended 31st March 2023 and year ended March 31,2023

			Amounts in Lakhs
Particulars		For the Year Ended	For the Half year ended
		March 31,2023	March 31,2023
Revenue			
Revenue from operations		9,916.89	5,358.17
Other income		136.09	53.58
	Total revenue	10,052.98	5,411.75
Expenses			
Cost of materials consumed		2,762.24	1,455.79
Employee benefit expenses		2,199.93	1,116.13
Finance costs		18.75	7.45
Depreciation and amortisation expense		259.79	144.26
Other expenses		4,169.03	2,417.70
	Total expenses	9,409.74	5,141.33
Profit / (loss) before prior period adjustments & tax.		643.24	270.42
Prior period adjustments		545.24	270.42
Profit / (loss) before extraordinary items and tax		643.24	270.42
Extraordinary items		0.0.24	270.42
Profit / (loss) before tax		643.24	270.42
Tax expense		043.24	270.42
Current tax		172.26	72.96
Deferred tax (expense)/income		(12.26)	(12.18)
Profit for the year		483.24	209.64
Profit / (loss) Share of Minority Interest	1	(0.05)	(0.05)
Profit/(Loss) for the period from continuing operations		483.29	209.69
Earnings per equity share		403.23	203.03
[Nominal value per share Rs. 10 (FY. 2021-22 - Rs.10)]			
Basic		4.60	1.99
Diluted		4.60	1.99

1) The Audited Financial statement were reviewed by the audit committee and taken on rcord by the Board of directors at their meeting held on 27th May, 2023

2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Audit Report on the aforesaid audited financial results for the half year & year ended 31st March. 2023, which were also approved by the Audit Committee and board at their meeting held on Saturday,27th May, 2023.

3) The Earning Per Sare (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).

4) As per MCA Notification Wited 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category. it has not adapted IND-AS for preparation of financial results.

5) The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Pubic Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below.

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	1452.78	147.22
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1825.76	147.22

6) The losses applicable to the minority in a consolidated subsidiary may exceed the minority interest in the equity of the subsidiary. The excess, and any further losses applicable to the minority, are adjusted against the majority interest except to the extent that the minority has a binding obligation to, and is able to, make good the losses. If the subsidiary subsequently reports profits, all such profits are allocated to the majority interest until the minority's share of losses previously absorbed by the majority has been recovered.

Being a first year of consolidated financial statements comparative figures are not given.

For A A Mohare and Co. Chartered Accountants (FRN 114152W) For and on behalf of the Board of Directors of

Vaidya Sane Ayurved Laboratories Ltd

Amit Mohare

Partner

Membership No. 148601 Place : Thane

Date: 27/05/2023 UDIN: 23 14860 18 GW JJO4191 **Rohit Sane**

MD & CEO DIN: 00679851

Date: 27/05/2023

Place: Thane

Vidyut Ghag

Date: 27/05/2023

Place : Thane

DIN: 09299252

Whole Time Director

Abhishek Deshpande

Darshan Shah

Company Secretary

Date: 27/05/2023

Place : Thane

Date: 27/05/2023 Place : Thane



culars	As at
	March 31, 202
TY AND LIABILITIES	
IT AND LIABILITIES	1
areholders' Funds	1
Share Capital	1,051.
Reserves and Surplus	2,993.
	4,045.
Minority interest	0.
3.	4,045
-	-
Deferred Tax Liabilities (Net)	
ong-Term Provisions	155.
	155.
	13.
(a) Total outstanding dues of micro enterprises and small enterprises	159.
	736.
	329.
nort-Term Provisions	48.
	1,287.
TOTAL	F 400
	5,488.
<u>'S</u>	
n-Current Assets	
Property, Plant & Equipment	
	1,843.
Intangible assets	- Constant
	251.
	167.
	153.
	7.5
ong-Term Loans and Advances	2,709.
	2,703
	1,379.
	341.3
	599.0
	176.4
	282.
the Current Assets	2,778.4
	2,776.
TOTAL	5,488.3
	areholders' Funds Share Capital Reserves and Surplus Minority interest In-Current Liabilities Long-Term Borrowings Deferred Tax Liabilities (Net) Long-Term Provisions Interest Interest Interest Interest In



Consolidated Cash flow statements for the year ended March 31, 2023

	Amounts in Lakhs
Particulars	For the year ended
A CARLET AND CORNEL COR	March 31, 2023
A. CASH FLOW FROM OPERATING ACTIVITIES :	
Net Profit before tax	643.24
Adjustments for:	
Depreciation and Amortization of Property, Plant and Equipment	259.79
Interest income	(87.27
Dividend income	(0.05
Minority interest	0.21
Rent income	(46.55
Excess balance written off	(2.04
Finance costs	18.75
Operating cash flows before Working Capital changes	786.08
Adjustments for Changes in Working Capital	
(Increase)/decrease in Inventories	(191.33
(Increase)/decrease in Trade Receivables	(244.44
(Increase)/decrease in Loans and Advances	(285.99
Increase/(decrease) in Trade Payables	161.98
Increase/(decrease) in Other Current Liabilities	32.21
Increase/(decrease) in Provisions	10.16
CASH GENERATED FROM OPERATIONS	268.67
Taxes Paid	(262.26
NET CASH FROM OPERATING ACTIVITIES	6.41
3. CASH FLOW FROM INVESTING ACTIVITIES	
Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets	(697.91
Investment in shares	(153.44
Proceeds from Fixed deposit	769.34
Dividend income	0.05
Rent Income	46.55
Interest Received	87.27
NET CASH USED IN INVESTING ACTIVITIES	51.86
C. CASH FLOW FROM FINANCING ACTIVITIES	
Proceeds from the issue of shares	
Share premium	
(Repayment) of Borrowings	
Proceeds from Borrowings	(92.93
Interim dividend paid	(26.28
Finance costs	(18.75)
NET CASH USED IN FINANCIAL ACTIVITIES	(137.96)
The same of the sa	(137.96)
Net increase in Cash and Cash Equivalents	(79.69
Cash and Cash Equivalents at beginning of the period	256.09
Cash and Cash Equivalents received on acquisition	
Exchange loss/ (gain) on translation of foreign currency cash	
Cash and Cash Equivalents as end of the period	176.40

CASH AND CASH EQUIVALENTS:

Particulars				As at March 31, 2023
On current accounts				158.46
Deposits with original maturity of less than 3 months				
Cash on hand				17.94
				176.40
As per our report of even date				
For A A Mohare and Co. Chartered Accountants (FRN 114152W) FRN 114152W		of the Board of Direct ved Laboratories Ltd	Marsparde	D.5.81
Amit Mohare	Rohit Sane	Vidyut Ghag	Abhishek Deshpande	Darshan Shah
	140 0 000	Whole Time Director	Company Secretary	
Partner ERED ACCOUNT	MD & CEO	whole time bliector		CFO
	DIN: 00679851	DIN: 09299252		CFO
Partner Membership No. 148601 Place : Thane		AND THE PROPERTY OF A PARTY OF A	Place : Thane	CFO Place : Thane

23 14860 18GWJJ04191



Vaidya Sane Ayurved Laboratories Ltd FI No. S. 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002 CIN NO. : L73100PN1999PLC013509 Standalone Statement of Segment Reporting for the Half year ended 31st March 2023 and year ended March 31,2023

		Hospital Activity	Activity			Sale of Product Activity	uct Activity			Common/ Unallocable	naflocable			Total	al	
Particulars	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022
REVENUE Segment Revenue	1,069.85	865.05	1,987.70	1,542.03	3,194.18	2,557.73	5,979.19	4,463.94	1,085.79	863.99	1,935.65	1,437.20	5,349.82	4,286.76	9,902.54	7,443.17
RESULT Other Segment Revenue									53.59	33,84	136.10	33.94	53.59	33.84	136.10	33.94
Material Consumed (Including direct	219.94	115.73	412.98	246.00	1,305.57	1,054.84	2,418.98	1,863.96		13.19	٠	17.93	1,525.51	1,183.76	2,831.97	2,127.88
Corporate Expenses	209.90	477.16	934.11	824.28	•				2,925.56	2,197.10	5,302.97	3,801.30	3,435.46	2,674.25	6,237.08	4,625.58
Operating Profit	340.01	272.16	640.60	471.75	1,888.61	1,502.89	3,560.21	2,599.98	(1,786.17)	(1,312.45)	(3,231.21)	(2,348.09)	442.44	462.59	969.60	723.64
nterest Cost						-	٠		7,45	9.30	18.74	20.18	7.45	9.30	18.74	20.18
Depreciation	16.27	20.23	28.85	20.23		(1)			128.02	90.89	230.97	208.34	144.29	111.12	259.82	228.57
Income Taxes		•			٠	3	•		72.96	101.89	172.26	119.14	72.96	101.89	172.26	119.14
Deferred Tax Provision				15					(0.14)	28.86	(0.22)	8.85	(0.14)	28.86	(0.22)	8.85
Net profit	323.74	251.93	611.75	451.52	1,888.61	1,502.89	3,560.21	2,599.98	(1,994.46)	(1,543.39)	(3,652.97)	(2,704.61)	217.89	211.43	519.00	346.89
<u>OTHER INFORMATION</u> Segment Assets Unallocate Corporate Assets	1,337.01	1,076.62	1,337.01	1,076.62					4,190.87	3,923.97	4,190.87	3,923.97	1,337.01	1,076.62	1,337.01	1,076.62
Fotal Assets	1,337.01	1,076.62	1,337.01	1,076.62					4,190.87	3,923.97	4,190.87	3,923.97	5,527.88	5,000.59	5,527.88	5,000.59
Segment Liabilities	123.86	137.89	123.86	137.89									123.86	137.89	123.86	137.89
Unallocate Corporate Liabilities									5,404.02	4,862.70	5,404.02	4,862.70	5,404.02	4,862.70	5,404.02	4,862.70
Fotal Liabilities	123.86	137.89	123.86	137.89					5,404.02	4,862.70	5,404.02	4,862.70	5,527.88	5,000.59	5,527.88	5,000.59
Capital Expenditure									566.13	216.92	765.46	293.53	566.13	216.92	765.46	293.53
Depreciation Non Cash Expenditure other than									128.02	90.89	230.97	208.34	128.02	90.89	230.97	208.34
Depreciation									4.48	(25.68)	(4.26)	(34.77)	4.48	(25.68)	(4.26)	(34.77)



aporatories (